Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 444

The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.

Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International Panel

Soriano, Vincent, Sulkowski, Mark, Bergin, Colm, Hatzakis, Angelos, Cacoub, Patrice, Katlama, Christine, Cargnel, Antonietta, Mauss, Stefan, Dieterich, Douglas, Moreno, Santiago, Ferrari, Carlo, Poynard, Thierry, Rockstroh, Jürgen · 2002 · AIDS

Abstract

Introduction A panel of experts met in Paris on 18 April to present research and practice protocols, and to discuss topics of current interest related to the treatment of HIV/hepatitis C virus (HCV) co-infection. The information presented focussed on the following main aspects: The magnitude of the problem of HIV/HCV co-infection The differences and similarities between HIV and HCV disease paradigms, thereby allowing extrapolation of the lessons learned in HIV on the care of patients with HCV or HIV/HCV co-infections Strategies for managing HIV in HCV-co-infected patients using antiretroviral drugs Current standards for HCV treatment and ongoing management Strategies for treating HCV in HIV-co-infected patients using pegylated interferon (peg-IFN) plus ribavirin, and the management of possible adverse effects Special challenges in HIV/HCV co-infection, including non-responders to IFN/ribavirin, patients with cirrhosis, extrahepatic manifestations, and hepatitis B virus co-infection. The bulk of the meeting was devoted to a discussion of the specifics of HIV/HCV co-infection treatment, answering the questions: why? how? who? when? After presentations and discussions, a consensus of opinion regarding general treatment strategy was formulated. Hepatitis C virus treatment in co-infected patients: why? AIDS-related morbidity and mortality in HIV-infected patients continue to decrease as a result of effective antiretroviral therapy and prophylaxis for traditional opportunistic infections [1]. HIV-infected patients now have hope for a prolonged AIDS-free survival. Concurrently, however, the morbidity and mortality from co-morbid HCV infection within this population is on the increase. The magnitude of the co-infection problem becomes clear when its prevalence and impact on morbidity and mortality are considered [2–9]. Prevalence of hepatitis C virus–HIV co-infection In the United States, it is estimated that 30% of the 800 000 HIV-infected living individuals are co-infected with HCV [10,11]. Similar rates (33%) have been estimated for western Europe, although the number of HIV-infected individuals is less well defined [12]. However, the magnitude of the problem is alarming in countries such as Spain, where at least half of the 130 000 HIV-infected patients are estimated to be HIV/HCV co-infected [12]. In fact, among some sub-groups of HIV-infected patients, such as injection drug users, the prevalence of co-infection is as high as 70–90% [11–13]. Hepatitis C virus and clinical progression of HIV disease The Swiss Cohort Study demonstrated that HCV accelerates the progression of HIV disease [14]. This prospective study of patients starting highly active antiretroviral therapy (HAART) found that HCV was independently associated with an increased risk of progression to AIDS and death. This finding was not related to a lower usage or much poorer tolerance of antiretroviral drugs among individuals with hepatitis C, which is in agreement with findings from other European groups [15]. Therefore, hepatitis C might be considered to be a co-factor for HIV disease progression. On the other hand, the Johns Hopkins Cohort Study found that co-infected patients who had a baseline CD4 cell count of between 50 and 200 cells/mm3 progressed to death more quickly than their HIV-mono-infected counterparts [16]. This observation probably highlighted the fact that HCV-positive patients, most of whom were intravenous drug addicts, had significantly less exposure to HAART, with a delay in treatment until CD4 cell counts dropped below 50 cells/mm3. In contrast with this potential deleterious effect of hepatitis C on HIV disease progression, recent reports [17,18] have pointed out that the hepatitis G virus, an agent closely related to HCV, seem to exert a protective effect on the course of HIV disease. As treatment of HCV with IFN is equally effective against hepatitis G, its clearance might negatively influence HIV infection. Hepatitis C virus and response to highly active antiretroviral therapy The Swiss Cohort Study also demonstrated that HCV may impair immune reconstitution after effective HAART [14]. HCV-positive individuals were less likely to achieve a CD4 cell increase of at least 50 cells/mm3 at one year after the start of HAART compared with HCV-negative individuals. This observation has not, however, been confirmed by others [19], and warrants further studies. HIV and acceleration of hepatitis C virus liver disease HIV accelerates HCV-related liver disease [20–25]. Progression that typically takes up to 30 years or longer in HCV-mono-infected individuals has been shown to take less than half that time in co-infected individuals. An early study by Martin et al. [26] identified the development of cirrhosis within 3 years after HCV diagnosis in three co-infected patients. In 1993, Eyster et al. [27] found that liver failure was accelerated by HIV in HCV-infected haemophiliac individuals. The following year, Telfer et al. [28] publi

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00002030-200204120-00001

Cites

128 of 128 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 128 references

Cited by

See all 444

Metadata

Authors
Soriano, V., Sulkowski, M., Bergin, C., Hatzakis, A., Cacoub, P., Katlama, C., Cargnel, A., Mauss, S., Dieterich, D., Moreno, S., Ferrari, C., Poynard, T., & Rockstroh, J.
Venue
AIDS
Published
2002-04
Volume
16
Issue
6
Pages
813-828
ISSN
0269-9370 (ISSN-L)
OpenAlex
W2059268470
Cited by
444
References
128
FWCI
30.16
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International Panel. https://app.cochat.ai/papers/10.1097/00002030-200204120-00001
The paper
Soriano, V., Sulkowski, M., Bergin, C., Hatzakis, A., Cacoub, P., Katlama, C., Cargnel, A., Mauss, S., Dieterich, D., Moreno, S., Ferrari, C., Poynard, T., & Rockstroh, J. (2002). Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International Panel. AIDS. https://doi.org/10.1097/00002030-200204120-00001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.